Mineral’s varied uses provide several avenues of exposure Are you one of the thousands of men...READ MORE
Baron & Budd, P.C. Sponsors Mesothelioma Patient Guidelines from NCCN
Guidelines Offer Latest Treatments and Medical Information on Malignant Pleural Mesothelioma
DALLAS –(July 12, 2011) –The national mesothelioma law firm of Baron and Budd has supported the new mesothelioma patient guidelines from the National Comprehensive Cancer Network® (NCCN®). Baron and Budd, mesothelioma lawyers, provided a generous donation to enable the distribution of the new resource, which is a translation of the professional NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ™) for Malignant Pleural Mesothelioma into patient-friendly materials. The new NCCN Guidelines for Patients™ for Malignant Pleural Mesothelioma are designed to help people with mesothelioma and their families better understand this asbestos-related cancer and treatment options and are now available for free on the NCCN consumer website, NCCN.com, and Baron and Budd’s dedicated website, Mesothelioma News.
“As a law firm committed to helping people affected by asbestos cancers, such as mesothelioma, we know how important it is for people to fully understand their medical options just as they need to know their legal options,” said Russell Budd, president and managing shareholder of Baron and Budd and board member of the NCCN Foundation. “We are honored to help bring such a valuable tool to mesothelioma patients.”
The NCCN Guidelines™ are developed by multidisciplinary panels of experts from NCCN Member Institutions and feature algorithms or “decision trees” that address every appropriate management option from initial work-up throughout the course of the disease. The NCCN Guidelines for Patients™ translate these professional guidelines in a clear, step-by-step manner that patients can use as the basis for making decisions and discussing treatment options with their physicians.
Dedicated to the many mesothelioma clients Baron and Budd has represented throughout the firm’s more than 30-year history, the NCCN Guidelines for Patients™focus on explaining mesothelioma as well as offering appropriate treatment options based on a patient’s individual needs. Treatment options discussed include surgery, chemotherapy and radiotherapy. The guidelines even include a comprehensive step-by-step guide to malignant pleural mesothelioma treatment, covering everything from stage I to stage IV mesothelioma.
Baron and Budd was one of the first law firms in the United States to successfully litigate a mesothelioma case and, under Russell Budd’s leadership, Baron and Budd has vigorously fought mesothelioma, both in the courtroom and through philanthropic efforts to advocate for victims and find a cure. Mr. Budd is a member of the Board of the NCCN Foundation and has been a shareholder of Baron & Budd since 1985 and president and managing shareholder since 2002. The firm was a cornerstone donor of the International Mesothelioma Program (IMP) at Brigham and Women’s Hospital and served on IMP’s Executive Advisory Board. Baron and Budd has also donated generously to the Asbestos Disease Awareness Organization (ADAO) and the Lung Cancer Alliance. The firm previously sponsored the book Understanding Mesothelioma from CURE magazine.
About Baron & Budd, P.C.
The national mesothelioma law firm of Baron & Budd, P.C. has a more than 30-year history of "Protecting What’s Right" for asbestos sufferers and their families. As one of the first law firms to successfully litigate an asbestos lawsuit, Baron & Budd continues to actively represent veterans, industry workers and others who are suffering as a result of exposure to asbestos. Baron & Budd achieved the largest mesothelioma verdict ever in the state of Texas, a $55 million verdict for an asbestos sufferer and his family in El Paso, Texas. Visit Baron & Budd’s dedicated mesothelioma website Mesothelioma News or call 1.866.855.1229 for information on medical treatments, mesothelioma cancer doctors and treatment centers, high risk jobs, veterans issues and financial assistance for asbestos cancer care.